Escherichia coli cell bank: development, characterization, and transfer for biopharmaceutical medicines production (review)

Introduction. Biological medicines produced using recombinant DNA technology play an important role in the international pharmaceutical market. Currently, bacterial and mammalian expression systems are widely used to produce recombinant proteins, monoclonal antibodies, and vaccines. To maintain the quality and stability of inoculation, cell banks are generated. Text. The general recommendations for cell bank development are outlined in the ICH Q5 guidelines. In the Russian Federation, similar requirements are specified in Decision No. 89 of the Council of the Eurasian Economic Commission "On approval of the Rules for assessments of biological medicines in the EAEU". Based on these requirements, one- or two-level cell banks should be established. Initially, a Master cell bank (MCB) is generated from a well-characterized single-cell bacterial colony according to high-quality standards. Subsequently, a Working cell bank (WCB) is created from one or several well-characterized MCB cryovials. As a result, the number of parameters required for WCB characterization can be reduced. The identity, purity, and stability of the cell bank should be determined. Requirements for cell bank characterization are detailed in official guidelines. An identity test is used to confirm the cell line or strain identification, which is a critical step to prevent cross-contamination and ensure the correct cell line in manufacturing processes. The absence of bacterial, fungal, or other types of contamination is demonstrated through purity testing. The sterility test is a key component, ensuring that a pure cell is used. The stability test demonstrates the genetic stability of the cells, including the preservation of genetic characteristics and the monitoring of harmful mutations during cultivation processes. Comprehensive data on the cell bank history, development, and characterization should be provided during its transfer. Conclusion. This research presents the general concept of microbial cell bank development, characterization, and transfer based on bacterial expression systems.

Authors

Institutions

Publication Details

Journal
Drug development & registration
Published
2025-08-05
DOI
https://doi.org/10.33380/2305-2066-2025-14-3-2064
Primary Topic
Viral Infectious Diseases and Gene Expression in Insects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Escherichia coli cell bank: development, characterization, and transfer for biopharmaceutical medicines production (review)

З. Р. Хасаншина, Анна Кучеренко, Р. В. Драй, E. A. Buslaeva et al.
Drug development & registration
Viral Infectious Diseases and Gene Expression in Insects
article

Escherichia coli cell bank: development, characterization, and transfer for biopharmaceutical medicines production (review)

З. Р. Хасаншина, Анна Кучеренко, Р. В. Драй, E. A. Buslaeva, S. А. Аlikina, L. М. Kriazhevskikh
article en

Abstract

Introduction. Biological medicines produced using recombinant DNA technology play an important role in the international pharmaceutical market. Currently, bacterial and mammalian expression systems are widely used to produce recombinant proteins, monoclonal antibodies, and vaccines. To maintain the quality and stability of inoculation, cell banks are generated. Text. The general recommendations for cell bank development are outlined in the ICH Q5 guidelines. In the Russian Federation, similar requirements are specified in Decision No. 89 of the Council of the Eurasian Economic Commission "On approval of the Rules for assessments of biological medicines in the EAEU". Based on these requirements, one- or two-level cell banks should be established. Initially, a Master cell bank (MCB) is generated from a well-characterized single-cell bacterial colony according to high-quality standards. Subsequently, a Working cell bank (WCB) is created from one or several well-characterized MCB cryovials. As a result, the number of parameters required for WCB characterization can be reduced. The identity, purity, and stability of the cell bank should be determined. Requirements for cell bank characterization are detailed in official guidelines. An identity test is used to confirm the cell line or strain identification, which is a critical step to prevent cross-contamination and ensure the correct cell line in manufacturing processes. The absence of bacterial, fungal, or other types of contamination is demonstrated through purity testing. The sterility test is a key component, ensuring that a pure cell is used. The stability test demonstrates the genetic stability of the cells, including the preservation of genetic characteristics and the monitoring of harmful mutations during cultivation processes. Comprehensive data on the cell bank history, development, and characterization should be provided during its transfer. Conclusion. This research presents the general concept of microbial cell bank development, characterization, and transfer based on bacterial expression systems.

Drug development & registration
ITMO University (RU), Saint-Petersburg State University Information Technologies, Mechanic and Optics (RU)
Openalex Percentile: Top 82%
Viral Infectious Diseases and Gene Expression in Insects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.